Checkpoint Therapeutics, Inc. said its lung cancer drug was well-tolerated and demonstrated anti-tumor activity in an early stage trial.
The phase 1/2 trial is evaluating CK-101, also known as RX518, in 19 patients with non-small cell lung cancer, the most common type of lung cancer.
Anti-tumor activity was particularly observed in patients having a mutation in the epidermal growth factor receptor, or EGFR, protein who had never undergone treatment before. Six out of these eight patients saw a reduction in tumor size but did not see their disease go away completely.
In six patients whose disease had spread to the brain, three patients saw a reduction in their cancer. A higher response rate was seen in patients who had a larger concentration of the drug in their bodies, with six out of 11 patients seeing tumor size reduction.
The company said there were no dose-limiting toxicities or treatment-related serious side effects.
Checkpoint said in a Sept. 6 news release that it plans to begin a phase 3 trial in EGFR mutation-positive non-small cell lung cancer patients who have not had prior treatment in 2019.